CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
9 citations
,
February 2002 in “International Journal of Dermatology” The patient's symptoms improved with treatment but recurred when the steroid dose was reduced, requiring ongoing therapy.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
IL-18 signaling helps mature Tregs move into the thymus.
May 2024 in “Indian Journal of Pharmacology” Tofacitinib effectively regrew scalp hair in an 11-year-old girl with alopecia areata.
8 citations
,
October 2023 in “Frontiers in Immunology” Certain cytokines may cause or be affected by immune skin diseases, suggesting possible new treatments.